Press "Enter" to skip to content

Novartis buys Takeda’s dry eye drug for $3.4 billion

Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd’s dry eye drug Xiidra for $3.4 billion, as well as potential milestone payments of up to $1.9 billion, to expand its portfolio of eye care medicines.

Original source:

Also Read:   J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample